Allogenic skeletal myoblast transplantation in acute myocardial infarction model rats

Transplantation

Volumn 91, Issue 4, 2011, Pages 425-431

  Imanishi, Yukiko ^a   Miyagawa, Shigeru ^a   Saito, Atsuhiro ^b   Kitagawa Sakakida, Satoru ^a,c   Sawa, Yoshiki ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c Takarazuka Dai ichi Hospital   (Japan)

Author keywords

Acute myocardial infarction; Allogenic; Cell transplantation; Donor cell survival; Immune rejection; Skeletal myoblast

Indexed keywords

GAMMA INTERFERON; HISTOCOMPATIBILITY ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ACUTE HEART INFARCTION; ALLOGENIC SKELETAL MYOBLAST TRANSPLANTATION; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY LIGATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT REJECTION; HEART EJECTION FRACTION; HISTOCOMPATIBILITY TEST; IMMUNE RESPONSE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOBLASTS, SKELETAL; MYOCARDIAL INFARCTION; RATS; RATS, INBRED LEW; RECEPTORS, INTERLEUKIN-2; STROKE VOLUME; TRANSPLANTATION, HOMOLOGOUS;

EID: 79951672360     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182052bca     Document Type: Article

References (32)

1. Herrmann JL, Abarbanell AM, Weil BR, et al. Cell-based therapy for isch-emic heart disease: A clinical update. Ann Thorac Surg 2009; 88: 1714.
2. Menasche P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: First randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189.
3. Schachinger V, Assmus B, Erbs S, et al. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: Insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009; 11: 973.
4. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113:1287.
5. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. CircRes 2004; 95: 9.
6. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: From culture to clinic. Exp Hematol 2008; 36: 733.
7. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277.
8. Imanishi Y, Saito A, Komoda H, et al. Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. JMol Cell Cardiol 2008; 44: 662.
9. Menasche P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol 2008; 45: 545.
10. Smythe GM, Hodgetts SI, Grounds MD. Immunobiology and the future of myoblast transfer therapy. Mol Ther 2000; 1: 304.
11. Chakkalakal JV, Thompson J, Parks RJ, et al. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. Faseb J 2005; 19: 880.
12. Rosen HR. Transplantation immunology: What the clinician needs to know for immunotherapy. Gastroenterology 2008; 134: 1789.
13. Merani S, Toso C, Emamaullee J, et al. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008; 95: 1449.
14. Reffet S, Thivolet C. Immunology of pancreatic islet transplantation. Diabetes Metab 2006; 32(5 pt 2): 523.
15. Benhamou PY. Immunomodulation with CTLA4-Ig in islet transplantation. Transplantation 2002; 73(1 suppl): S40.
16. Guo C, Haider H, Wang C, et al. Myoblast transplantation for cardiac repair: From automyoblast to allomyoblast transplantation. Ann Thorac Surg2008; 86: 1841.
17. Simpson E, Scott D, James E, et al. Minor H antigens: Genes and peptides. Eur J Immunogenet 2001; 28: 505.
18. Simpson E, Scott D, Chandler P. The male-specific histocompatibility antigen, H-Y: A history of transplantation, immune response genes, sex determination and expression cloning. Annu Rev Immunol 1997; 15:39.
19. + T-helper cells in H-Y-mismatched transplantation. Lancet 2003; 362: 610.
20. Kitagawa-Sakakida S, Tori M, Li Z, et al. Active cell migration in re-transplanted rat cardiac allografts during the course of chronic rejection. J Heart Lung Transplant 2000; 19: 584.
21. Wollert KC, Drexler H. Cell-based therapy for heart failure. Curr Opin Cardiol 2006; 21: 234.
22. Uemura R, Xu M, Ahmad N, et al. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006; 98: 1414.
23. Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair.Proc Natl Acad Sci USA2007; 104: 1643.
24. Farahmand P, Lai TY, Weisel RD, et al. Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation 2008; 118(14 suppl): S130.
25. Perez-Ilzarbe M, Agbulut O, Pelacho B, et al. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur J Heart Fail 2008; 10: 1065.
26. Burchfield JS, Iwasaki M, Koyanagi M, et al. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res 2008; 103: 203.
27. Menasche P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 2007; 50: 7.
28. Suzuki K, Murtuza B, Beauchamp JR, et al. Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. Faseb J 2004; 18: 1153.
29. Guo C, Haider H, Shim WS, et al. Myoblast-based cardiac repair: Xe-nomyoblast versus allomyoblast transplantation. J Thorac Cardiovasc Surg 2007; 134: 1332.
30. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275.
31. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389.
32. MiyagawaS, Sawa Y, TaketaniS, et al. Myocardial regeneration therapy for heart failure: Hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002; 105: 2556.